Pelthos Therapeutics Inc. Compensation Expense, Excluding Cost of Good and Service Sold
Pelthos Therapeutics Inc. (PTHS) reported Compensation Expense, Excluding Cost of Good and Service Sold of $0 for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold · last filed 2025-08-13
- Pelthos Therapeutics Inc. compensation expense, excluding cost of good and service sold for the quarter ending 2025-06-30 was $0.00.
- Pelthos Therapeutics Inc. compensation expense, excluding cost of good and service sold for the quarter ending 2024-06-30 was $0.00.
| Period end | Compensation Expense, Excluding Cost of Good and Service Sold 3 month | Compensation Expense, Excluding Cost of Good and Service Sold 6 month |
|---|---|---|
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |